Objective To investigate the influence of obesity on curative effect of inhaling Budesonide in children with bronchial asthma (BA). Methods A total of 120 children with BA admitted into our hospital from January 2015 to May 2016 were involved in this study. Patients were divided into normal weight group (19 kg/m2 to 25 kg/m2, n = 57), overweight group (25 kg/m2 to 30 kg/m2, n = 42), obesity group (over 30 kg/m2, n = 21) according to body mass index (BMI). All children were inhaled with Budesonide in treatment of asthma. Nerve growth factor (NGF), interleukin 4 (IL-4), immunoglobulin E (IgE), gamma interferon (IFN-gamma), forced vital capacity (FVC), the first second forced breathing volume (FEV1) and supreme respiratory flow (PEF) were determined. Curative efficacy and adverse reactions were recorded. Results Effective rate in normal weight group, overweight group and obesity group was 94.74%, 80.95% and 76.19%, respectively; statistically significant difference among three groups was identified (P < 0.05).Treatment of Budesonide induced significant improvement of FEV1 and FVC among three groups (P < 0.05) when compared with that prior to therapy, while no difference of PEF was observed before and post treatment.Therapeutic efficacy was compromised obviously in obesity group and overweight group compared with normal weight group (P < 0.05). Treatment of Budesonide induced significant improvement of NGF, IL-4, IgE and IFN-gamma among three groups (P < 0.05) when compared with that prior to therapy (P < 0.05). Improvement of NGF, IL-4, IgE and IFN-gamma was shrunkenin obesity group and over weight group when compared with those in normal weight group (P < 0.05). Adverse reactions in normal weight group, overweight group and obesity group was 7.02%, 7.14% and 9.52%, respectively; there was no statistically significant difference incidence of adverse reactions among three groups. Conclusions Obese children with BA experience compromised therapeutic effect of inhaling Budesonide.